Samraat Raha - Agilent Technologies President
| A Stock | USD 133.87 2.08 1.53% |
President
Mr. Samraat S. Raha serves as Senior Vice President, President, Diagnostics and Genomics Group of the Company. He has served as our Senior Vice President, Agilent and President, Diagnostics and Genomics Group since April 2018. From May 2017 to April 2018, Mr. Raha served as our Senior Vice President, Strategy and Corporationrationrate Development. From June 2013 to January 2017 he served as Vice President, Global Marketing for Illumina, Inc. and from 2008 to 2012 he served as Vice President and General Manager, Genomic Assays NextGen qPCR for Life Technologies, Inc. since 2018.
| Age | 51 |
| Tenure | 8 years |
| Phone | 800 227 9770 |
| Web | https://www.agilent.com |
Samraat Raha Latest Insider Activity
Tracking and analyzing the buying and selling activities of Samraat Raha against Agilent Technologies stock is an integral part of due diligence when investing in Agilent Technologies. Samraat Raha insider activity provides valuable insight into whether Agilent Technologies is net buyers or sellers over its current business cycle. Note, Agilent Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell Agilent Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Samraat Raha over a month ago Disposition of 29634 shares by Samraat Raha of Myriad Genetics at 7.3 subject to Rule 16b-3 | ||
Samraat Raha over six months ago Acquisition by Samraat Raha of 1498 shares of Myriad Genetics at 3.562 subject to Rule 16b-3 |
Agilent Technologies Management Efficiency
The company has return on total asset of 0.0849 % which means that for every 100 dollars spent on assets, it generated a profit of $0.0849. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2062 %, implying that it made 0.2062 on every $100 invested by shareholders. Agilent Technologies' management efficiency ratios could be used to measure how well Agilent Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Patricia English | Cardinal Health | 44 | |
| Christopher Reidy | Becton Dickinson and | 64 | |
| Ian Bell | Alcon AG | 55 | |
| Donald Bobo | Edwards Lifesciences Corp | 64 | |
| JeanLuc Lemercier | Edwards Lifesciences Corp | 69 | |
| Wendy Stewart | IQVIA Holdings | N/A | |
| Cynthia Verst | IQVIA Holdings | N/A | |
| James Borzi | Becton Dickinson and | 49 | |
| Michael McDonnell | IQVIA Holdings | 55 | |
| Lisa Paley | Haleon plc | 59 | |
| Rob Schlissberg | Cardinal Health | N/A | |
| Jorge Sahlieh | Cardinal Health | N/A | |
| David Wilson | Cardinal Health | 57 | |
| Raj Sodhi | ResMed Inc | 45 | |
| SueJean Lin | Alcon AG | 65 | |
| Michael Pintek | Cardinal Health | 56 | |
| Nilton Paletta | IQVIA Holdings | N/A | |
| Huimin Wang | Edwards Lifesciences Corp | 64 | |
| Charles Bodner | Becton Dickinson and | 46 | |
| Jon Resnick | IQVIA Holdings | N/A | |
| Kevin Knightly | IQVIA Holdings | 63 | |
Management Performance
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0849 |
Agilent Technologies Leadership Team
Elected by the shareholders, the Agilent Technologies' board of directors comprises two types of representatives: Agilent Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agilent. The board's role is to monitor Agilent Technologies' management team and ensure that shareholders' interests are well served. Agilent Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agilent Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip Binns, Senior Group | ||
| Padraig McDonnell, Senior Vice President and Presidentident - Agilent CrossLab Group | ||
| Daniel Podolsky, Independent Director | ||
| Hans Bishop, Independent Director | ||
| George Scangos, Independent Director | ||
| Sue Rataj, Independent Director | ||
| Parmeet Ahuja, Vice Relations | ||
| Jacob Thaysen, Senior Vice President, Agilent, President - Life Sciences and Applied Markets Group | ||
| Darlene Solomon, CTO VP | ||
| Samraat Raha, Senior Vice President, Agilent, President - Diagnostics and Genomics Group | ||
| Tejas Savant, Vice Relations | ||
| Paul Clark, Independent Director | ||
| Mala Anand, Independent Director | ||
| Jenipher Dalton, Chief VP | ||
| Robert McMahon, Chief Financial Officer, Senior Vice President | ||
| John Kohl, Senior Officer | ||
| Chris Swenson, VP Officer | ||
| Mikael Dolsten, Independent Director | ||
| Allison Ballmer, Vice President - Strategy and Corporate Development | ||
| August Specht, Senior Officer | ||
| Michael McMullen, CEO and President Director and Member of Executive Committee | ||
| Rodney Gonsalves, Chief Accounting Officer, Vice President, Corporate Controllership | ||
| Henrik AncherJensen, Senior Vice President, Agilent and President - Order Fulfillment | ||
| Dow Wilson, Independent Director | ||
| Diana Chiu, Interim VP | ||
| Heidi Kunz, Independent Director | ||
| Angelica III, Senior President | ||
| Otis Brawley, Independent Director | ||
| Bret DiMarco, Chief VP | ||
| Simon May, SVP Group | ||
| Frederick Schwarz, Chief SVP | ||
| Jonah Kirkwood, Senior Organization | ||
| Dominique Grau, Senior Vice President of Human Resources and Global Communications | ||
| Susan Rataj, Independent Director | ||
| Robert CMA, Senior CFO | ||
| Adam Elinoff, CFO VP | ||
| Michael Tang, Senior Vice President General Counsel, Secretary | ||
| Tadataka Yamada, Independent Director | ||
| Meghan Henson, Senior Officer | ||
| Henrick AncherJensen, Senior Chain | ||
| Katharine Knobil, Chief Medical Officer. | ||
| Boon Koh, Non-Executive Independent Chairman of the Board | ||
| Yvonne Mackie, MD Europe |
Agilent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agilent Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0849 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 40.11 B | |||
| Shares Outstanding | 283.5 M | |||
| Shares Owned By Insiders | 0.31 % | |||
| Shares Owned By Institutions | 93.03 % | |||
| Number Of Shares Shorted | 3.85 M | |||
| Price To Earning | 37.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agilent Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Agilent Stock refer to our How to Trade Agilent Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agilent Technologies. If investors know Agilent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Agilent Technologies assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Agilent Technologies is measured differently than its book value, which is the value of Agilent that is recorded on the company's balance sheet. Investors also form their own opinion of Agilent Technologies' value that differs from its market value or its book value, called intrinsic value, which is Agilent Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agilent Technologies' market value can be influenced by many factors that don't directly affect Agilent Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Agilent Technologies' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agilent Technologies represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Agilent Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.